literature

HBV mutation literature information.

Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.

PMID: 26336997 2015 Current medicinal chemistry

Abstract: In this regard, homology modeled structure of HBV polymerase was used for minimization, conformational search and Glide XP docking followed by binding energy calculation on wild-type as well as on mutant HBV-polymerases (N236T, L180M+M204V+S202G & A194T).

Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.

PMID: 25712861 2015 Journal of medical virology

Abstract: No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L).

Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.

PMID: 26322642 2015 PloS one

Introduction: They include rtI169T, rtL180M, rtS184S/A/I/L/G/C/M, M204I/V, rtS202G/I, and rtM250I/V.

Table: S202G

4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.

PMID: 26122273 2015 Hepatology (Baltimore, Md.)

Abstract: Once-daily peroral administration of CAdA reduced HBVETV-RL180M/S202G/M204V viremia (P = 0.0005) in human-liver-chimeric/ HBVETV-RL180M/S202G/M204V-infected mice, whereas ETV completely failed to reduce HBVETV-RL180M/S202G/M204V viremia.

Abstract: Southern analysis using Huh-7 cells transfected with HBV-containing plasmids demonstrated that CAdA was potent against both wild-type (IC50= 7.2 nM) and ETV-resistant HBV (IC50= 69.6 nM for HBVETV-RL180M/S202G/M204V), whereas ETV failed to reduce HBVETV-RL180M/

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.

PMID: 25061278 2014 Drug design, development and therapy

Abstract: Amino acid substitutions of rtL180M, rtS202G, and rtM204V emerged and were associated with an increase in serum HBV DNA at virologic breakthrough.

Conclusion: In comparison with those at the start of TDF therapy, the amino acid substitutions changed from rtL180M, rtT184M, and rtM204V to rtL180M, rtS202G, and rtM204V, and no other amino acid substitut

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.

PMID: 24993731 2014 Intervirology

Abstract: The rtT184L/I/A/F (50%), rtS202G (25%) and mixed ETV-resistant mutations (25%) were detected at enrollment.

Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.

PMID: 24788140 2014 PloS one

Result: It is worth noting that we did not observe any of the common NA-related resistance mutations including rtM204V/I, rtS202C/G/I, rtL180M, rtA181T/V, rtT184A/I/L/G/C/M, rtA194T, rtI169T, rtV173L, rtL80I, rtN236T, and

PMID: 24697270 2014 The Journal of organic chemistry

Abstract: FMCA demonstrated excellent anti-HBV activity against both adefovir-resistant and lamivudine-resistant double (rtL180M/rtM204V) mutants as well as in lamivudine/entecavir triple mutants (L180M+S202G+M204V) in vitro.

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients.

PMID: 23596461 2013 Hepatitis monthly

Table: S202I/G

Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.

PMID: 22878399 2013 Antiviral therapy

Abstract: All clones had >=1 of the S202G, T184F, T184A, T184L, T184I and M250V ETV resistance mutations.

Browser Board

Co-occurred Entities

Filtrator